YU53899A - Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja - Google Patents
Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećajaInfo
- Publication number
- YU53899A YU53899A YU53899A YU53899A YU53899A YU 53899 A YU53899 A YU 53899A YU 53899 A YU53899 A YU 53899A YU 53899 A YU53899 A YU 53899A YU 53899 A YU53899 A YU 53899A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- cyclooxygenase
- inhibitors
- derivatives
- cardiovascular disorders
- preventing cardiovascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Pronalazak se odnosi na upotrebu inhibitora ciklooksigenaze-2 ili njihovih derivata u proizvodnji leka za prevenciju kardiovaskularnih poremećaja, uključujući upale koje su u vezi sa kardiovaskularnim bolestima. Inhibitori ciklooksigenaze-2 uključuju 5,5-dimetil-4-4(metilsufonil)fenil)-3-(2-propoksi(-5H-furan-2-on; 5-metanesulfonamid-6-(2,4-difluorotiofenil)-1-indanon; i izabrane derivate sulfonifenilena[This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4462697P | 1997-04-18 | 1997-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU53899A true YU53899A (sh) | 2002-10-18 |
Family
ID=21933403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU53899A YU53899A (sh) | 1997-04-18 | 1998-04-16 | Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja |
Country Status (26)
Country | Link |
---|---|
EP (2) | EP1498140A2 (sh) |
JP (1) | JP2001527542A (sh) |
KR (1) | KR20010006443A (sh) |
CN (1) | CN1253502A (sh) |
AP (1) | AP9901674A0 (sh) |
AU (1) | AU745797B2 (sh) |
BG (1) | BG103803A (sh) |
BR (1) | BR9808932A (sh) |
CA (1) | CA2286673A1 (sh) |
EA (1) | EA199900837A1 (sh) |
EE (2) | EE9900517A (sh) |
GE (1) | GEP20022812B (sh) |
HU (1) | HUP0001777A3 (sh) |
ID (1) | ID23687A (sh) |
IL (1) | IL132163A0 (sh) |
IS (1) | IS5203A (sh) |
NO (1) | NO995077L (sh) |
NZ (1) | NZ500141A (sh) |
OA (1) | OA11261A (sh) |
PL (1) | PL337098A1 (sh) |
SK (1) | SK138799A3 (sh) |
TR (1) | TR199902545T2 (sh) |
UA (1) | UA68348C2 (sh) |
WO (1) | WO1998047509A1 (sh) |
YU (1) | YU53899A (sh) |
ZA (1) | ZA983249B (sh) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
US7030152B1 (en) * | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
EP1767222A1 (en) * | 1999-08-31 | 2007-03-28 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
EP1520590A1 (en) * | 1999-08-31 | 2005-04-06 | The Brigham and Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
JP2003508453A (ja) * | 1999-08-31 | 2003-03-04 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー |
UA76475C2 (en) * | 2001-07-19 | 2006-08-15 | Pharmacia Corp | Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system |
AU2002362443B2 (en) | 2001-10-01 | 2008-05-15 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
KR100686537B1 (ko) * | 2001-12-28 | 2007-02-27 | 씨제이 주식회사 | 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체 |
US20050123580A1 (en) * | 2002-02-28 | 2005-06-09 | Burris Thomas P. | Method of treating atherosclerosis and hypercholesterolemia |
CA2494164A1 (en) | 2002-08-23 | 2004-03-04 | Rigel Pharmaceuticals, Inc. | Pyridyl substituted heterocycles useful for treating or preventing hcv infection |
EP1400243A1 (en) * | 2002-09-19 | 2004-03-24 | Tanabe Seiyaku Co., Ltd. | Calcium-activated K channel activator |
JP2004189711A (ja) * | 2002-12-11 | 2004-07-08 | Raul Altman | 急性冠動脈症候群および関連病態の治療のための抗血小板薬と組合せたメロキシカムの使用 |
EP1590336B1 (en) | 2003-01-27 | 2010-12-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
WO2004099164A1 (en) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
US7326790B2 (en) | 2003-05-02 | 2008-02-05 | Rigel Pharmaceuticals, Inc. | Diphenylisoxazole compounds and hydro isomers thereof |
ES2275218T3 (es) | 2003-05-07 | 2007-06-01 | Osteologix A/S | Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos. |
US7220745B2 (en) | 2003-05-15 | 2007-05-22 | Rigel Pharmaceuticals | Heterocyclic compounds useful to treat HCV |
WO2005049065A2 (en) | 2003-11-19 | 2005-06-02 | Rigel Pharmaceuticals, Inc. | Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
US7514434B2 (en) | 2004-02-23 | 2009-04-07 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof |
AU2005252183B2 (en) | 2004-06-04 | 2008-07-17 | Merck Sharp & Dohme Corp. | Pyrazole derivatives, compositions containing such compounds and methods of use |
WO2006028618A1 (en) | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
EP2266994B1 (en) | 2004-08-02 | 2013-04-03 | University Of Virginia Patent Foundation | 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity |
US7442687B2 (en) | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
WO2007027230A2 (en) | 2005-05-02 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses |
US20070037797A1 (en) * | 2005-08-15 | 2007-02-15 | Hellstrom Harold R | Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events |
US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
WO2010114896A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
CN104105478A (zh) | 2011-10-28 | 2014-10-15 | 维塔利斯公司 | 抗发红组合物 |
CN115671097B (zh) * | 2022-08-23 | 2024-02-13 | 上海交通大学医学院附属第九人民医院 | 用于防治动脉粥样硬化及斑块不稳定性的化合物及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3103372A1 (de) * | 1981-01-27 | 1982-09-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue indanyl-derivate, ihre herstellung und verwendung |
JP2893903B2 (ja) * | 1990-09-12 | 1999-05-24 | 藤沢薬品工業株式会社 | 虚血―再灌流障害予防、治療剤 |
JP3086312B2 (ja) * | 1991-10-28 | 2000-09-11 | 富山化学工業株式会社 | インターロイキン6の産生抑制剤並びにその産生抑制作用が有効な疾患の治療・予防剤 |
US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5344991A (en) * | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
RO118291B1 (ro) * | 1993-11-30 | 2003-04-30 | Searle & Co | Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine |
US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
US5393790A (en) * | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
EP0772606A1 (en) * | 1994-07-27 | 1997-05-14 | G.D. SEARLE & CO. | Substituted thiazoles for the treatment of inflammation |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
ES2183935T3 (es) * | 1995-02-13 | 2003-04-01 | Searle & Co | Isoxazoles sustituidos para el tratamiento de la inflamacion. |
CA2221692A1 (en) * | 1995-05-19 | 1996-11-21 | G.D. Searle & Co. | Substituted oxazoles for the treatment of inflammation |
CA2223154A1 (en) * | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US5643933A (en) * | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
CA2224563A1 (en) * | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations |
ATE301457T1 (de) * | 1995-06-12 | 2005-08-15 | Searle & Co | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
GB9520584D0 (en) * | 1995-10-09 | 1995-12-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
-
1998
- 1998-04-16 EP EP04023890A patent/EP1498140A2/en not_active Withdrawn
- 1998-04-16 IL IL13216398A patent/IL132163A0/xx not_active IP Right Cessation
- 1998-04-16 NZ NZ500141A patent/NZ500141A/en unknown
- 1998-04-16 AP APAP/P/1999/001674A patent/AP9901674A0/en unknown
- 1998-04-16 CA CA002286673A patent/CA2286673A1/en not_active Abandoned
- 1998-04-16 EA EA199900837A patent/EA199900837A1/ru unknown
- 1998-04-16 KR KR1019997009533A patent/KR20010006443A/ko active Search and Examination
- 1998-04-16 TR TR1999/02545T patent/TR199902545T2/xx unknown
- 1998-04-16 EP EP98922028A patent/EP0979077A1/en not_active Withdrawn
- 1998-04-16 PL PL98337098A patent/PL337098A1/xx unknown
- 1998-04-16 JP JP54611398A patent/JP2001527542A/ja not_active Withdrawn
- 1998-04-16 SK SK1387-99A patent/SK138799A3/sk unknown
- 1998-04-16 YU YU53899A patent/YU53899A/sh unknown
- 1998-04-16 ID IDW991219A patent/ID23687A/id unknown
- 1998-04-16 EE EEP199900517A patent/EE9900517A/xx unknown
- 1998-04-16 HU HU0001777A patent/HUP0001777A3/hu unknown
- 1998-04-16 GE GEAP19985037A patent/GEP20022812B/en unknown
- 1998-04-16 AU AU74662/98A patent/AU745797B2/en not_active Ceased
- 1998-04-16 CN CN98804252A patent/CN1253502A/zh active Pending
- 1998-04-16 WO PCT/US1998/007318 patent/WO1998047509A1/en not_active Application Discontinuation
- 1998-04-16 BR BR9808932-3A patent/BR9808932A/pt not_active Application Discontinuation
- 1998-04-16 UA UA99105689A patent/UA68348C2/uk unknown
- 1998-04-16 EE EEP200300169A patent/EE200300169A/xx unknown
- 1998-04-17 ZA ZA983249A patent/ZA983249B/xx unknown
-
1999
- 1999-09-30 IS IS5203A patent/IS5203A/is unknown
- 1999-10-13 BG BG103803A patent/BG103803A/bg unknown
- 1999-10-18 OA OA9900228A patent/OA11261A/en unknown
- 1999-10-18 NO NO995077A patent/NO995077L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL337098A1 (en) | 2000-07-31 |
CN1253502A (zh) | 2000-05-17 |
NO995077L (no) | 1999-12-17 |
AU745797B2 (en) | 2002-03-28 |
UA68348C2 (en) | 2004-08-16 |
WO1998047509A1 (en) | 1998-10-29 |
EE200300169A (et) | 2003-06-16 |
EP1498140A2 (en) | 2005-01-19 |
EA199900837A1 (ru) | 2000-10-30 |
EE9900517A (et) | 2000-06-15 |
NO995077D0 (no) | 1999-10-18 |
OA11261A (en) | 2003-07-24 |
EP0979077A1 (en) | 2000-02-16 |
NZ500141A (en) | 2002-05-31 |
HUP0001777A3 (en) | 2001-07-30 |
CA2286673A1 (en) | 1998-10-29 |
ID23687A (id) | 2000-05-11 |
AU7466298A (en) | 1998-11-13 |
KR20010006443A (ko) | 2001-01-26 |
BR9808932A (pt) | 2000-08-01 |
BG103803A (bg) | 2000-05-31 |
JP2001527542A (ja) | 2001-12-25 |
IS5203A (is) | 1999-09-30 |
TR199902545T2 (xx) | 2000-01-21 |
GEP20022812B (en) | 2002-10-25 |
IL132163A0 (en) | 2001-03-19 |
SK138799A3 (en) | 2001-01-18 |
AP9901674A0 (en) | 1999-12-31 |
HUP0001777A2 (hu) | 2001-05-28 |
ZA983249B (en) | 1999-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU53899A (sh) | Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja | |
IL164568A0 (en) | Compounds and methods for the inhibition of the expression of vcam-1 | |
HK1023767A1 (en) | Substituted pyridines as selective cyclooxygenase-2 inhibitors and the composition thereof. | |
YU15299A (sh) | Farmaceutski sastavi | |
DK0760848T3 (da) | Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf | |
PL331900A1 (en) | 1,4-heterocyclic inhibitors of metaloprotease | |
HK1033095A1 (en) | Inhibitor of lipoprotein oxidation. | |
ZA981132B (en) | Methods, compositions and articles for reducing or preventing the effects of inflammation. | |
PL331838A1 (en) | 1,3-diheterocyclic inhibitors of metaloproteases | |
HK1041407A1 (en) | Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors. | |
ZA973146B (en) | Prodrugs of COX-2 inhibitors. | |
AU2001284690A1 (en) | Compositions exhibiting synergistic inhibition of the expression and/or activityof cyclooxygenase-2 | |
NO990296D0 (no) | HPPD-genet og inhibitorer | |
HK1020261A1 (en) | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | |
IL127918A0 (en) | Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations | |
ZA9811629B (en) | The use of MMP inhibitors for the treatment of ocular angiogenesis. | |
HK1033096A1 (en) | Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculationdisorders | |
WO1998022101A3 (en) | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents | |
HK1048318B (zh) | 取代的3-苯基-5-烷氧基-1,3,4-噁二唑-2-酮及其作為脂酶抑制劑的用途 | |
IL144199A0 (en) | Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
NO991542D0 (no) | Anvendelse av svake stÕllegeringer for antikoksing | |
IL106237A0 (en) | Piperidyl amides,sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis | |
EP1144305A4 (en) | NEW sPLA 2 INHIBITORS | |
IL139144A0 (en) | Mycobacterial inhibitors | |
PT1042288E (pt) | Inibidores de tripeptidil peptidase |